Nimbus Therapeutics Appoints Abbas Kazimi CEO
Nimbus Therapeutics, LLC, a biotechnology company focused on designing and developing breakthrough medicines through its advanced computational drug discovery platform, has announced the appointment of Abbas Kazimi, MS, as its new Chief Executive Officer and a member of the Board of Directors, effective immediately. Kazimi succeeds Jeb Keiper, MS, MBA, who has stepped down as part of a planned leadership transition.
Nimbus Therapeutics, a biotechnology company known for its innovative small molecule drug discovery, has announced a new phase of leadership with the appointment of Abbas Kazimi, MS, as its Chief Executive Officer and a member of the Board of Directors, effective immediately. Kazimi’s appointment marks a critical milestone in the company’s evolution as he takes over the role from Jeb Keiper, MS, MBA, who steps down as part of a planned leadership transition.
Bruce Booth, D. Phil., Chairman of the Board of Directors and co-founder of Nimbus, expressed his full support for Kazimi, stating, “We are excited to announce the next chapter in leadership at Nimbus. The board is unanimous in its support of Abbas, who has been a critical leader in the last decade of success at Nimbus.
With the recent appointment of Peter Tummino, Ph.D., as President of R&D and the strong leadership team in place, we are confident Abbas will continue to deliver on the company’s mission to bring breakthrough medicines to patients.” Booth also thanked Jeb Keiper for his contributions to the company, acknowledging his passion and leadership in shaping Nimbus into the powerhouse it is today. “We have immense respect for what he has done to build the Nimbus we know today,” said Booth.
Jeb Keiper also shared his thoughts on the leadership transition, expressing pride in the company’s growth during his tenure. “After spending over a decade at Nimbus, I couldn’t be more proud of the incredible team we’ve built and our evolution into a world-class small molecule discovery and early development powerhouse,” said Keiper.
He went on to express his confidence in Kazimi’s ability to lead Nimbus through its next phase, stating, “In this next phase of growth, I can think of no better leader than Abbas, who has led this team in creating an incredibly valuable biotech company. I look forward to seeing Nimbus continue to advance its promising pipeline under his leadership while I pursue time with my family, biotech boards, and philanthropies that impact our industry.”
Abbas Kazimi joined Nimbus in 2014 and has played a key role in the company’s growth and strategic direction. Since 2020, he has served as Chief Business Officer, where he drove several major transactions that resulted in over $7 billion in upfront and milestone capital from pharmaceutical partners.
Notably, Kazimi played a pivotal role in the sale of TYK2 to Takeda in 2022. Additionally, Kazimi has been instrumental in expanding Nimbus’ computational drug discovery engine through technology alliances that have strengthened the company’s deep expertise in structure-based drug discovery and medicinal chemistry.
“I am honored to lead Nimbus at this pivotal time in the company’s evolution,” said Kazimi upon his appointment. “Our robust pipeline, anchored by promising programs like our WRN and SIK inhibitors, and our ongoing collaboration with Lilly, continues to validate our approach and strengthen our position in the industry. I’m particularly excited about what Nimbus will continue to discover and advance, as we leverage our computational drug discovery engine to bring innovative medicines for patients.”
Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company that focuses on developing novel small molecule medicines targeting difficult-to-drug, validated targets in various human diseases.
The company employs a unique strategy that combines cutting-edge computational technologies with machine learning-based predictive modeling approaches to accelerate drug discovery. Nimbus’ promising pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor currently in development for microsatellite instability-high (MSI-H) tumors. Additionally, the company has a diverse portfolio of preclinical programs targeting cancer, autoimmune conditions, and metabolic diseases.
Nimbus’ headquarters is located in Boston, Massachusetts, where the company continues to push the boundaries of drug discovery and development. With Abbas Kazimi at the helm, Nimbus is poised to build on its track record of success, advancing its innovative therapies and making meaningful strides toward delivering breakthrough treatments for patients.
As Nimbus embarks on this exciting new chapter under Kazimi’s leadership, the company’s dedication to transforming drug discovery through computational technologies and a patient-centered approach remains steadfast. With the strength of its leadership team, strategic partnerships, and a promising pipeline, Nimbus Therapeutics is well-positioned for continued growth and success in the biopharmaceutical industry.
